ArticleEpidemiology and infection2017
Outbreak of KPC-3-producing ST15 and ST348 Klebsiella pneumoniae in a Portuguese hospital.
Article in Epidemiology and infection, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Investigating the prevalence of KPC-2 and the variant KPC-144 in carbapenem-resistant Klebsiella pneumoniae and elucidating its molecular epidemiological and genetic characteristics.BMC microbiology · 2026Article
- Microbiological characterization and clinical outcomes of carbapenem-resistant enterobacterales infections in a paediatric hospital in Mexico.BMC infectious diseases · 2026Observational
- Hospital-Based Genomic Surveillance ofBiology · 2025Article
- Prevalence and features of hypervirulentInfection and immunity · 2025Review
- Epidemiological Characteristics and Carbapenemase Analysis of Carbapenem-Resistant Enterobacterales Isolates in a Teaching Hospital in Guangzhou, China.Infection and drug resistance · 2025Article
- Molecular and virulence differences ofFrontiers in microbiology · 2025Article
- Tackling Carbapenem Resistance and the Imperative for One Health Strategies-Insights from the Portuguese Perspective.Antibiotics (Basel, Switzerland) · 2024Review
- Activity of Epsilon-poly-L-lysine against Multidrug-ResistantBiomedicines · 2024Article
- Article
- Genomic Analysis of Carbapenem-Resistant HypervirulentInfection and drug resistance · 2023Article
- Multicenter Genomic Analysis of Carbapenem-Resistant Klebsiella pneumoniae from Bacteremia in China.Microbiology spectrum · 2022Article
- TEM,CTX-M,SHV Genes in ESBL-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- Whole-Genome Sequencing Enables Molecular Characterization of Non-Clonal Group 258 High-Risk Clones (ST13, ST17, ST147 and ST307) among Carbapenem-ResistantMicroorganisms · 2022Article
- Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Review
- Environmental and Pathogenic Carbapenem Resistant Bacteria Isolated from a Wastewater Treatment Plant Harbour Distinct Antibiotic Resistance Mechanisms.Antibiotics (Basel, Switzerland) · 2021Article
- Characterization of ESBL-ProducingMicroorganisms · 2021Article
- Intra- and Extra-Hospital Dissemination of IMP-22-ProducingFrontiers in microbiology · 2021Article
- Characterization of Carbapenem-ResistantInfection and drug resistance · 2021Article
- Multidrug-resistant Klebsiella pneumoniae harboring extended spectrum β-lactamase encoding genes isolated from human septicemias.PloS one · 2021Article
- An Emerging Clone, Klebsiellapneumoniae Carbapenemase 2-Producing K. pneumoniae Sequence Type 16, Associated With High Mortality Rates in a CC258-Endemic Setting.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, only a few sporadic cases of infections due to Klebsiella pneumoniae carbapenemase (KPC) producers have been reported in Portugal. Here, we report for the first time an outbreak of K. pneumoniae KPC-3 producers in a tertiary-care hospital during 2013. Twenty-seven ertapenem-resistant K. pneumoniae were identified in patients at a tertiary-care hospital during 2013 isolated predominantly from urine (48·1%) and blood (25·9%) cultures. All isolates were highly resistant to β-lactam antibiotics and most showed intermediate resistance to imipenem. The more frequent β-lactamases were TEM- (77·7%), CTX-M- (70·3%) and KPC-type (66·6%). KPC-3 was identified by sequencing. The bla KPC-3 gene was associated with an IncF plasmid, and efficiently transferred to E. coli J53. Pulsed-field gel electrophoresis typing revealed three clusters of isolates which were further characterized by multi-locus sequence typing as ST11, ST15 and ST348. Ertapenem-resistant ST15 was already in circulation in the hospital, related to expression of OmpK36 modified porin, but the other two sequence types had not been previously found in the hospital. We conclude that the IncF plasmid mediated transfer of KPC-3 in the outbreak and that implementation of carbapenemase gene screening in isolates from patients on admission to hospital is advisable in order to control dissemination of these antimicrobial resistance elements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.